Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice
Longevity of the immune response following viral exposure is an essential aspect of SARS-CoV-2 infection. Mild SARS-CoV-2 infection of K18-hACE2 mice was implemented for evaluating the mounting and longevity of a specific memory immune response. We show that the infection of K18-hACE2 mice induced robust humoral and cellular immunity (systemic and local), which persisted for at least six months. Virus-specific T cells and neutralizing antibody titers decreased over time, yet their levels were sufficient to provide sterile immunity against lethal rechallenge six months post-primary infection. The study substantiates the role of naturally induced immunity against SARS-CoV-2 infection for preventing recurring morbidity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Vaccines - 10(2022), 4 vom: 14. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bar-On, Liat [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines10040613 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339845333 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339845333 | ||
| 003 | DE-627 | ||
| 005 | 20231226003814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines10040613 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339845333 | ||
| 035 | |a (NLM)35455362 | ||
| 035 | |a (PII)613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bar-On, Liat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Longevity of the immune response following viral exposure is an essential aspect of SARS-CoV-2 infection. Mild SARS-CoV-2 infection of K18-hACE2 mice was implemented for evaluating the mounting and longevity of a specific memory immune response. We show that the infection of K18-hACE2 mice induced robust humoral and cellular immunity (systemic and local), which persisted for at least six months. Virus-specific T cells and neutralizing antibody titers decreased over time, yet their levels were sufficient to provide sterile immunity against lethal rechallenge six months post-primary infection. The study substantiates the role of naturally induced immunity against SARS-CoV-2 infection for preventing recurring morbidity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a K18-hACE2 mice | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a mild infection | |
| 700 | 1 | |a Aftalion, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Makdasi, Efi |e verfasserin |4 aut | |
| 700 | 1 | |a Gur, David |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalay, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Hila |e verfasserin |4 aut | |
| 700 | 1 | |a Beth-Din, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenfeld, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Achdout, Hagit |e verfasserin |4 aut | |
| 700 | 1 | |a Bar-Haim, Erez |e verfasserin |4 aut | |
| 700 | 1 | |a Falach, Reut |e verfasserin |4 aut | |
| 700 | 1 | |a Chitlaru, Theodor |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Ofer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 10(2022), 4 vom: 14. Apr. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:4 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines10040613 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 4 |b 14 |c 04 | ||